Participated · Equity · Jul 2025

AbsoluteCare delivers a whole-person, PCP-led care model called Beyond Medicine™ that combines social determinants of health support, behavioral health, primary and urgent care, and integrated pharmacy. The company focuses on high-acuity Medicaid and Medicare members who average 13 diagnoses, take 10+ medications, and for whom 60% have a behavioral health or substance-use diagnosis. AbsoluteCare reports strong outcomes in its internal 2025 data, including a 34% reduction in emergency department visits, a 20–30% decrease in total cost of care, and 75–80% member engagement after one year. It operates comprehensive care centers in urban communities and extends care through hospital rounding and in-home visits. Headquartered in Columbia, Maryland, AbsoluteCare currently operates in 11 markets including Baltimore, Chicago, multiple Ohio cities, New Orleans, Philadelphia, and Pittsburgh. The company says it will continue scaling its concierge, PCP-led model and expand into new markets and member populations. AbsoluteCARE operates a patient-centered ambulatory intensive caring unit delivery model that serves complex, high-utilizing patients and functions as their primary care provider. The company emphasizes integrated primary care plus wrap-around services that address social determinants of health, including past trauma, addiction, food insecurity, and housing instability. AbsoluteCARE currently operates five facilities in Atlanta; Baltimore (2); Prince George’s County, Maryland; and Philadelphia, and since 2000 has treated tens of thousands of high-acuity, chronically ill patients. The business leverages population health management tools and extensive patient outreach to improve outcomes and lower costs for insurance partners. Leadership describes plans to expand interventions that address social determinants of health and to scale their model to serve vulnerable populations more broadly.

Participated · Series C · Jul 2022

Sovrn operates a multi-solution publisher technology platform delivering advertising technology, affiliate monetization tools, reader engagement measurement, and privacy-compliant data enrichment. Led by CEO Walter Knapp and based in Boulder, Colorado, the company provides tools for content creators to understand, operate and grow their businesses. Its affiliate suite includes link creation, commerce comparisons, shopping galleries and access to thousands of merchants, while its advertising stack focuses on inventory management and reporting. Since a previous $26M raise in December 2018, Sovrn has acquired three companies, expanded its product portfolio, increased headcount by more than 50% across the US, UK and EU, and added thousands of active customers. Those customers generate hundreds of millions of dollars in annual revenue using Sovrn’s products. The company plans to use new funding to pursue additional acquisitions and to develop products and services that expand its platform capabilities. sovrn is an ad tech company and partner to almost 50,000 websites on the independent web, offering tools and services to help publishers understand audiences and monetize through programmatic advertising. The company processes about one billion ad transactions every day across its publisher network. sovrn positions itself as an advocate for independent publishers and supplies analytics, growth and engagement tools alongside monetization services. Management plans to use new capital to accelerate both organic expansion and inorganic growth opportunities. Financially, sovrn reported year‑over‑year revenue growth of 90% in the second quarter and has delivered four consecutive quarters of positive EBITDA. The company is headquartered in Boulder, Colo., with offices in Denver, San Francisco and New York. Lijit Networks builds custom site search and advertising solutions for online publishers, operating a programmatic advertising services platform and publisher network. Its network includes more than 17,000 websites, about 1.5 billion pageviews per month and over 106 million unique visitors per month. The company reports that transactions on its advertising services platform have grown 74% since Q4 2010. Lijit was founded in June 2006. The article reports the company has raised $28.3 million to date. No future product plans are specified in the article. Lijit Networks supplies search and content-discovery tools to individual publishers, commercial websites and content networks to surface reader intent, behavior, content and demographics. Its products aim to enhance engagement, lengthen time on site and increase page views. The company launched an Advertising Services platform which it plans to accelerate with new capital. The recent financing will also support growth of Lijit’s publisher network. Lijit is incorporated in 2006 and is based in Boulder, CO. To date the company has raised $17M in total capital.

Participated · Equity · Oct 2017

KSQ Therapeutics has built a genome-scale functional-genomics drug discovery engine called CRISPRomics to pinpoint therapeutic targets and guide high-confidence drug development. Using CRISPRomics, the company has generated and advanced more than a dozen oncology drug programs, initiating 12 programs across adoptive T-cell therapies, immuno-oncology, and targeted therapies in the past 12 months. Its first program is a modified adoptive T-cell immunotherapy that has shown efficacy in multiple animal models of PD-1 resistant solid tumors. KSQ plans to advance that first program into the clinic within the next 18 months and to move up to three additional oncology programs into IND-enabling studies. The company is also expanding CRISPRomics into other therapeutic areas, including immunology and rare diseases. KSQ is located in Cambridge, Massachusetts. KSQ Therapeutics built a genome-scale precision functional genomics platform called CRISPRomics to systematically elucidate the function of human genes across disease models. The company has deployed CRISPRomics to complete functional assessment of each gene in more than 600 tumor and immune models, generating insights used to define novel therapeutic nodes and drug combinations. KSQ is advancing a proprietary pipeline of oncology- and immunology-focused drug development programs derived from those genome-scale insights. The company emphasizes patient-tailored, high-confidence drug development intended to shorten timelines and increase the likelihood of meaningful clinical impact. KSQ has appointed an experienced industry executive team and grown to more than 40 employees. The company announced a $76 million financing to support its platform-driven drug discovery efforts.

Participated · Equity · Dec 2014

CardioKinetix is a Menlo Park, Calif.–based medical device company pioneering the catheter-based Parachute® Ventricular Partitioning Device to treat heart failure. The Parachute implant is delivered via a femoral artery catheter to partition the left ventricle, exclude non-functional segments, reduce overall left-ventricular volume, and restore geometry and function in a minimally invasive procedure performed in the catheterization laboratory. The Parachute system received CE Mark in 2011 and is investigational in the U.S., limited to investigational use only. The company reports more than 300 patients treated, four clinical trials completed, and 23 publications on the Parachute therapy. CardioKinetix completed a $50 million financing that will fund the PARACHUTE IV randomized pivotal trial, support a U.S. pre-market approval (PMA) submission, and enable international market development efforts. The PARACHUTE IV study is currently enrolling patients in the United States and its data will form the basis of the company’s PMA submission to the FDA. CardioKinetix is a Menlo Park, CA-based medical device company developing the Parachute Ventricular Partitioning Device, a catheter-delivered, minimally invasive implant for patients with heart failure due to post‑MI damage. The Parachute implant is deployed via a catheter inserted in the femoral artery to partition the left ventricle, excluding non-functional myocardium to reduce LV volume and restore geometry and function. The procedure is performed in the catheterization laboratory under conscious sedation. The device has received CE Mark; in the U.S. it is an investigational device limited by federal law to investigational use only. The company is led by President and CEO Maria Sainz and is advancing its programs to bring the Parachute therapy to market. Recent financing activity supports further clinical and commercialization efforts. CardioKinetix is a Menlo Park, CA-based medical device company that developed the PARACHUTE™ Ventricular Partitioning Device, a transcatheter implant for the left ventricle. The Parachute device is intended to treat patients with heart failure resulting from a myocardial infarction and is implanted via a catheter lab procedure. The device recently received the CE Mark and the company is conducting clinical studies in Europe. The FDA has approved an IDE Pivotal Trial for Parachute based on results from a feasibility study. The company is led by President and CEO Wes Johnson. CardioKinetix completed a $44M two-tranche Series E financing, reflecting its ongoing clinical and regulatory progress.